Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) had its price objective boosted by stock analysts at Argus from $42.00 to $50.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Argus‘s target price suggests a potential upside of 19.39% from the company’s current price.
TEVA has been the topic of a number of other research reports. TD Cowen boosted their price target on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research report on Friday, September 4th. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the stock an “overweight” rating in a research note on Thursday, October 15th. Leerink Partners boosted their target price on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday, November 5th. Finally, Oppenheimer upped their price target on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, October 9th. Fourteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $48.43.
Read Our Latest Research Report on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Trading Down 1.6%
Shares of TEVA traded down $0.69 during mid-day trading on Tuesday, reaching $41.88. 1,742,121 shares of the company were exchanged, compared to its average volume of 6,841,446. Teva Pharmaceutical Industries has a 52 week low of $24.01 and a 52 week high of $44.57. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.74 and a current ratio of 0.95. The stock has a market capitalization of $48.80 billion, a PE ratio of 97.40, a PEG ratio of 4.09 and a beta of 0.97. The business has a 50 day simple moving average of $40.29 and a two-hundred day simple moving average of $35.12.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.72 by $0.14. The business had revenue of $4.39 billion for the quarter, compared to analysts’ expectations of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The firm’s revenue was down 1.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.78 earnings per share. On average, analysts predict that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current fiscal year.
Insider Activity
In other Teva Pharmaceutical Industries news, CEO Richard Francis sold 250,000 shares of the firm’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $42.24, for a total value of $10,560,000.00. Following the transaction, the chief executive officer directly owned 927,529 shares of the company’s stock, valued at approximately $39,178,824.96. This trade represents a 21.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Richard Daniell sold 25,000 shares of the firm’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $42.91, for a total transaction of $1,072,750.00. Following the completion of the transaction, the executive vice president directly owned 55,755 shares in the company, valued at $2,392,447.05. This trade represents a 30.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 715,945 shares of company stock valued at $29,061,351. 0.54% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Teva Pharmaceutical Industries
Hedge funds have recently added to or reduced their stakes in the stock. Migdal Insurance & Financial Holdings Ltd. increased its holdings in Teva Pharmaceutical Industries by 1.3% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 39,422,212 shares of the company’s stock worth $1,561,120,000 after purchasing an additional 500,000 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Teva Pharmaceutical Industries by 20.0% in the third quarter. Goldman Sachs Group Inc. now owns 7,355,669 shares of the company’s stock worth $291,284,000 after purchasing an additional 1,226,429 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Teva Pharmaceutical Industries by 5.8% in the second quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock valued at $259,899,000 after purchasing an additional 419,329 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Teva Pharmaceutical Industries by 1.5% in the first quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company’s stock valued at $145,076,000 after purchasing an additional 72,880 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in shares of Teva Pharmaceutical Industries by 28.7% in the first quarter. Swiss National Bank now owns 4,227,900 shares of the company’s stock valued at $127,344,000 after purchasing an additional 941,700 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
See Also
- Five stocks we like better than Teva Pharmaceutical Industries
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
